NeoGenomics, Inc. Q1 2026 Financial Results: Key Investor Insights
NeoGenomics, Inc. Reports First Quarter 2026 Financial Results: Key Insights for Investors
Overview
NeoGenomics, Inc. has released its financial results for the first quarter of 2026, offering important updates on its operating performance, revised guidance, and several items of potential shareholder interest. The results, as disclosed in an SEC Form 8-K and accompanying press release, contain a mix of positive developments and ongoing challenges for the company.
Key Highlights
- Positive Adjusted EBITDA: Adjusted EBITDA for Q1 2026 was \$9 million, marking a substantial 27% increase compared to \$7.1 million in Q1 2025.
- Return to Adjusted Net Income: Adjusted Net Income was \$1.4 million, a significant improvement from an Adjusted Net Loss of \$0.5 million in Q1 2025.
- Strong Liquidity Position: Cash, cash equivalents, and marketable securities totaled \$146 million at the quarter’s end.
- Revised Full-Year Guidance: The company updated its FY 2026 guidance, originally issued on February 17, 2026, reflecting expectations for continued growth and improved profitability.
Detailed Financial Results
Operating Performance: The 27% year-over-year increase in Adjusted EBITDA signals improved operational efficiency and cost management. The shift from an Adjusted Net Loss to Adjusted Net Income is particularly important for investors, as it demonstrates the company’s progress toward sustained profitability.
Cash Flow: Despite positive adjusted earnings, NeoGenomics reported a GAAP net loss of \$25.9 million for the quarter. Net cash used in operating activities was \$8.1 million, and net cash used in investing activities was \$5 million. There was also a minor net cash outflow from financing activities (\$338,000), offset by a net inflow of \$949,000 in the prior year.
Balance Sheet: At quarter end, total stockholders’ equity stood at \$828.8 million, up from \$836.6 million at the end of Q1 2025. Current liabilities were \$517.8 million, compared to \$523.3 million in the prior period.
Revised FY 2026 Guidance (In Millions)
| Metric |
Low Range |
High Range |
YOY % Change |
| Net Loss (GAAP) |
\$(30) |
\$(30) |
N/A |
| Stock-Based Compensation Expense |
\$43 |
\$40 |
N/A |
| Depreciation |
\$39 |
\$36 |
N/A |
| Adjusted Net Income (Non-GAAP) |
\$21 |
\$27 |
N/A |
| Adjusted EBITDA (Non-GAAP) |
\$21 |
\$27 |
N/A |
Adjusted diluted EPS guidance for 2026 is projected at \$0.21 per share, with weighted average assumed shares outstanding at 130 million.
Non-GAAP Measures & Use
NeoGenomics emphasizes the use of non-GAAP financial measures (Adjusted EBITDA, Adjusted Net Income, Adjusted Gross Profit Margin, Adjusted Diluted EPS) to provide investors with a clearer understanding of the company’s core operating performance. These measures exclude items such as stock-based compensation, interest, taxes, and CEO transition costs, allowing for a more meaningful analysis of recurring business results.
Noteworthy Risks and Forward-Looking Statements
The company’s press release contains forward-looking statements regarding its strategy, growth opportunities, new test offerings, and market expansion. Management cautions that actual results may differ materially due to risks such as:
- Regulatory changes affecting laboratory-developed tests
- Tariffs and trade policy uncertainty impacting supply chains
- Potential reimbursement changes by government and commercial payors
- Ability to execute on strategic priorities and integrate acquisitions
- Identified risks in the company’s Annual Report and other SEC filings
Shareholder-Relevant Items
- Return to Adjusted Profitability: If sustained, this could be price-sensitive and signal a turning point in operational performance.
- Revised Guidance: Upward revisions in adjusted net income and EBITDA may positively influence investor sentiment and share price.
- Cash Position: Strong liquidity reduces risk and supports continued investment.
- Risks: Persistent GAAP net losses, regulatory uncertainty, and reimbursement risks remain important factors that could affect future valuation.
Contacts
Investor Contact: [email protected]
Media Contact: Andrea Sampson
Disclaimer: This article is intended for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. The information is based on the company’s public filings and press releases. Investors are encouraged to review NeoGenomics, Inc.’s SEC filings and consult with their financial advisor before making investment decisions. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those projected.
View NEOGENOMICS INC Historical chart here
